Supplemental Figure 2 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

Alexandre Bazinet; Sai Prasad Desikan; Ziyi Li; Juan José Rodríguez‐Sevilla; Sangeetha Venugopal; Samuel Urrutia; Guillermo Montalban‐Bravo; Koji Sasaki; Kelly S. Chien; Danielle Hammond; Rashmi Kanagal‐Shamanna; Irene Gañán‐Gómez; Tapan M. Kadia; Gautam Borthakur; Courtney D. DiNardo; Naval Daver; Elias Jabbour; Farhad Ravandi; Hagop M. Kantarjian; Guillermo Garcia‐Manero

doi:10.1158/1078-0432.25515466

Abstract

Supplemental Figure 2: Overall survival and event-free survival in HMA-naïve patients with HR-MDS treated with HMA plus venetoclax versus a contemporary cohort treated with HMA monotherapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bazinet et al. (2024) studied this question.

synapsesocial.com/papers/68e712c7b6db64358768bbef https://doi.org/10.1158/1078-0432.25515466

View Full Paper

Ask AI

Bookmark

Abstract

Supplemental Figure 2: Overall survival and event-free survival in HMA-naïve patients with HR-MDS treated with HMA plus venetoclax versus a contemporary cohort treated with HMA monotherapy.

Supplemental Figure 2 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

Abstract

Discussion

Cite This Study

Supplemental Figure 2 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

Abstract

Discussion

Cite This Study

Keep reading

Keep reading